Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0000921895-25-003215 0002098271 XXXXXXXX LIVE 2 Common Stock, par value $0.00001 per share 12/29/2025 false 0001482541 86887P309 CEA Industries Inc. 1780 55TH STREET, SUITE C BOULDER CO 80301 JIA "HOLLY" YOU 201-855-6358 YZILABS MANAGEMENT LTD. 2 Fl, Water's Edge Bldg, Wickhams Cay II Road Town D8 VG 110 0002098271 N YZILabs Management Ltd. a WC N D8 0.00 2150481.00 0.00 2150481.00 2150481.00 N 4.9 CO Y Changpeng Zhao a AF Y C0 0.00 2150481.00 0.00 2150481.00 2150481.00 N 4.9 IN HC 0001906587 N Baucus Sieben Max a N X1 0.00 0.00 0.00 0.00 0.00 N 0 IN Y Chapman James David a N X0 0.00 0.00 0.00 0.00 0.00 N 0 IN Mr. Chapman is a citizen of the United Kingdom and Australia. Y Guillen Goody Teresa Marie a N X1 0.00 0.00 0.00 0.00 0.00 N 0 IN Ms. Goody Guillen is a citizen of the United States and Australia. Y He Jiajin a PF N F4 2099644.00 0.00 2099644.00 0.00 2099644.00 N 4.6 IN Y Odagiu Alex a PF N X0 4918.00 0.00 4918.00 0.00 4918.00 N 0.01 IN Mr. Odagiu is a citizen of the United Kingdom, Moldova and Romania. Y Roszak Matthew a N X1 0.00 0.00 0.00 0.00 0.00 N 0 IN Mr. Roszak is a citizen of the United States and Poland. Y Zhang Ling a N U0 0.00 0.00 0.00 0.00 0.00 N 0 IN Common Stock, par value $0.00001 per share CEA Industries Inc. 1780 55TH STREET, SUITE C BOULDER CO 80301 Item 4 is hereby supplemented to add the following: On December 29, 2025, the Issuer announced that it had adopted a poison pill rights plan and adopted Amended and Restated Bylaws of the Company (the "Bylaws") which added significant restrictions and procedural hurdles to the process of nominating director candidates to the Board and soliciting the written consent of stockholders of the Issuer. Among the newly instituted requirements for soliciting written consents in the Bylaws is the submission by a soliciting stockholder to the Issuer of lengthy and onerous disclosure far exceeding the requirements under federal securities laws in the form of a written request to the Issuer to set a record date for such written consent. The Bylaws further require that this request letter attach a written questionnaire and written representation and agreement completed by each proposed director nominee in a form provided by the Issuer upon the written request of a stockholder of the Issuer. Pursuant to the Bylaws, each such nominee must also represent and warrant to the Issuer that he or she will, if elected, be in compliance with all guidelines and policies of the Issuer applicable to directors, which guidelines and policies will be provided to such potential director nominee upon written request to the Issuer. Also on December 29, 2025, in order to comply with these new rules and restrictions in respect of its previously announced solicitation of consents to, among other things, expand the size of the Board and appoint each of its Nominees to the Board to fill the resulting vacancies, YZi Labs delivered a written request to the Issuer for the form of such questionnaire and representation and agreement. Further, Ms. Zhang, as a potential director nominee of YZi Labs, delivered a written request to the Issuer for such guidelines and policies. YZILabs Management Ltd. /s/ Ling Zhang Ling Zhang, Authorized Signatory 12/31/2025 Changpeng Zhao /s/ Changpeng Zhao Changpeng Zhao 12/31/2025 Baucus Sieben Max /s/ Max Sieben Baucus Max Sieben Baucus 12/31/2025 Chapman James David /s/ Ling Zhang Ling Zhang, Attorney-in-fact for David J. Chapman 12/31/2025 Guillen Goody Teresa Marie /s/ Ling Zhang Ling Zhang, Attorney-in-fact for Teresa Marie Goody Guillen 12/31/2025 He Jiajin /s/ Ling Zhang Ling Zhang, Attorney-in-fact for Jiajin He 12/31/2025 Odagiu Alex /s/ Ling Zhang Ling Zhang, Attorney-in-fact for Alex Odagiu 12/31/2025 Roszak Matthew /s/ Ling Zhang Ling Zhang, Attorney-in-fact for Matthew Roszak 12/31/2025 Zhang Ling /s/ Ling Zhang Ling Zhang 12/31/2025